Torre Lazur McCann names Ouimette as president

Torre Lazur McCann, formerly the BioGenesis Group, named Michael Ouimette as president. He joins from Pacific Communications, where he was senior vice president for client services. In addition to directing strategic development, he managed the integration of three communication groups, including account services, medical education and managed care. Ouimette will report to Beverly Breitenbach, chief executive of the parent organization's U.S. subsidiary.
As president, Ouimette is responsible for the overall management and success of Torre Lazur West, as well as for new business development. Current clients include Chiron, Gilead Sciences and Avanir.
"Michael was brought in to recharge the West Coast agency, providing the vision and drive to consolidate its strategic direction with those of the other agencies under our corporate roof," explained Breitenbach, who is based at the company's official headquarters in Parsippany, N.J. She added that the decision to change the agency's name was part of a nationwide reorganization. "We wanted to reflect a single image and philosophy, telling clients that we're not biotech or pharma, not professional or consumer, but the right agency for any healthcare marketing assignment."
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.